Oettle H, Arnold D, Hempel C, Riess H
Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultät der Humboldt Universität zu Berlin, Germany.
Anticancer Drugs. 2000 Nov;11(10):771-86. doi: 10.1097/00001813-200011000-00001.
Pancreatic cancer, one of the most frequently reported gastrointestinal tumors, has a 5-year survival of less than 5%. Despite representing only 2-3% of the total cancer incidence, it is the fifth leading cause of cancer death. This is because it is commonly only diagnosed at an advanced stage. Until recently the traditional therapy for patients with advanced disease was palliative 5-fluorouracil (5-FU)-based chemotherapy. However, the novel antinucleoside gemcitabine (Gemzar) has demonstrated a survival benefit over 5-FU, and an improvement in disease-related symptoms and quality of life in patients with advanced disease. This review presents an overview of the clinical studies of gemcitabine, either alone or in combination, with other chemotherapeutic agents and/or radiation therapy, in the treatment of these patients. A comparison of these studies is made with those using alternative treatment regimens. The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared.
胰腺癌是最常报道的胃肠道肿瘤之一，其5年生存率低于5%。尽管它仅占癌症总发病率的2%-3%，却是癌症死亡的第五大主要原因。这是因为它通常在晚期才被诊断出来。直到最近，晚期疾病患者的传统治疗方法还是基于5-氟尿嘧啶（5-FU）的姑息化疗。然而，新型抗核苷吉西他滨（健择）已显示出比5-FU更能延长生存期，并且能改善晚期疾病患者的疾病相关症状和生活质量。本综述概述了吉西他滨单独或与其他化疗药物和/或放射治疗联合用于治疗这些患者的临床研究。将这些研究与使用替代治疗方案的研究进行了比较。数据表明，吉西他滨联合生物调节的5-FU应被视为标准的姑息治疗方法，其他新的药物组合或联合放化疗方案应与之进行比较。
